Tags

Type your tag names separated by a space and hit enter

Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease.
Dig Dis Sci 2011; 56(11):3112-21DD

Abstract

Diverticular disease is a common bowel condition, the pathogenesis of which is incompletely understood. Acute exacerbations of diverticular disease usually require dietary changes, antibiotic therapy, and may necessitate urgent surgery. Approximately 25-33% of patients experience symptomatic and acute inflammatory disease recurrence, suggesting that current long-term management is inadequate. Because inflammatory complications of diverticular disease, including diverticulitis, are similarities to inflammatory bowel diseases, evidence suggests that patients may respond to anti-inflammatory therapies used in these conditions. Here, we explore the rationale and evidence for use of inflammatory bowel disease treatment, namely 5-aminosalicylic acid (5-ASA; mesalamine), in diverticular disease, and review clinical data on the efficacy of mesalamine either alone or in combination with other agents for the treatment of diverticular disease. PubMed and conference abstracts were searched for clinical studies examining the use of mesalamine in treating diverticular disease. Studies were evaluated for treatment efficacy in symptom reduction, recurrence prevention, or improving quality of life. The results of our search suggest that single-agent mesalamine can reduce diverticular disease symptoms and improve quality of life more effectively than antibiotic treatment alone. Mesalamine in combination with antibiotics can also reduce symptoms and improve quality of life with greater efficacy than either treatment alone. Combining mesalamine and probiotics treatments may reduce recurrent attacks of diverticular disease. Further randomized, well-controlled studies are required for validation; however, it seems that mesalamine is an important agent in future diverticular disease management.

Authors+Show Affiliations

Gastroenterology Service, ASL BAT, Via Torino, 49, 76123 Andria, BT, Italy. antotursi@tiscali.itNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21567193

Citation

Tursi, Antonio, et al. "Expanding Applications: the Potential Usage of 5-aminosalicylic Acid in Diverticular Disease." Digestive Diseases and Sciences, vol. 56, no. 11, 2011, pp. 3112-21.
Tursi A, Joseph RE, Streck P. Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Dig Dis Sci. 2011;56(11):3112-21.
Tursi, A., Joseph, R. E., & Streck, P. (2011). Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Digestive Diseases and Sciences, 56(11), pp. 3112-21. doi:10.1007/s10620-011-1731-x.
Tursi A, Joseph RE, Streck P. Expanding Applications: the Potential Usage of 5-aminosalicylic Acid in Diverticular Disease. Dig Dis Sci. 2011;56(11):3112-21. PubMed PMID: 21567193.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. AU - Tursi,Antonio, AU - Joseph,Raymond E, AU - Streck,Paul, Y1 - 2011/05/13/ PY - 2010/10/19/received PY - 2011/04/18/accepted PY - 2011/5/14/entrez PY - 2011/5/14/pubmed PY - 2011/12/28/medline SP - 3112 EP - 21 JF - Digestive diseases and sciences JO - Dig. Dis. Sci. VL - 56 IS - 11 N2 - Diverticular disease is a common bowel condition, the pathogenesis of which is incompletely understood. Acute exacerbations of diverticular disease usually require dietary changes, antibiotic therapy, and may necessitate urgent surgery. Approximately 25-33% of patients experience symptomatic and acute inflammatory disease recurrence, suggesting that current long-term management is inadequate. Because inflammatory complications of diverticular disease, including diverticulitis, are similarities to inflammatory bowel diseases, evidence suggests that patients may respond to anti-inflammatory therapies used in these conditions. Here, we explore the rationale and evidence for use of inflammatory bowel disease treatment, namely 5-aminosalicylic acid (5-ASA; mesalamine), in diverticular disease, and review clinical data on the efficacy of mesalamine either alone or in combination with other agents for the treatment of diverticular disease. PubMed and conference abstracts were searched for clinical studies examining the use of mesalamine in treating diverticular disease. Studies were evaluated for treatment efficacy in symptom reduction, recurrence prevention, or improving quality of life. The results of our search suggest that single-agent mesalamine can reduce diverticular disease symptoms and improve quality of life more effectively than antibiotic treatment alone. Mesalamine in combination with antibiotics can also reduce symptoms and improve quality of life with greater efficacy than either treatment alone. Combining mesalamine and probiotics treatments may reduce recurrent attacks of diverticular disease. Further randomized, well-controlled studies are required for validation; however, it seems that mesalamine is an important agent in future diverticular disease management. SN - 1573-2568 UR - https://www.unboundmedicine.com/medline/citation/21567193/Expanding_applications:_the_potential_usage_of_5_aminosalicylic_acid_in_diverticular_disease_ L2 - https://doi.org/10.1007/s10620-011-1731-x DB - PRIME DP - Unbound Medicine ER -